News GSK wins FDA green light for chronic hep B treatment Hibsago GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.
News GSK hails 'unprecedented' cure rates with hep B drug The B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.
News GSK enlists local aid for Chinese rollout of hep B drug GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.
News GSK eyes October FDA verdict on chronic hep B drug GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.
News GSK preps filings for chronic hepatitis B drug bepirovirsen GSK will file its chronic hepatitis B virus therapy bepirovirsen for approval in the first quarter, after it hit the mark in two phase 3 trials.
News FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker th
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.